Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed Plc LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.00 -0.94% 1,050.00 1,058.00 1,066.00 1,076.00 1,050.00 1,050.00 35,333 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 86.4 12.6 20.0 52.5 520

Ergomed plc Ergomed to Present at Jefferies Conference 2021

15/11/2021 7:00am

RNS Non-Regulatory


TIDMERGO

Ergomed plc

15 November 2021

PRESS RELEASE

Ergomed to Present at Jefferies London Healthcare Conference 2021

Guildford, UK - 15 November 2021: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces that Dr Miroslav Reljanovi ć, Executive Chairman of Ergomed, will present at the Jefferies London Healthcare Conference at 8am GMT on 16 November 2021.

The presentation will be available on Ergomed's website, here:

https://ergomedplc.com/news-and-events/

ENDS

Enquiries :

Ergomed plc Tel: +44 (0) 1483 402 975

Dr Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Numis Securities Limited Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)

James Black (Broker)

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden

   Consilium Strategic Communications                                       Tel: +44 (0) 20 3709 5700 

Chris Gardner / Matthew Neal ergomed@consilium-comms.com

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGPGRWGUPGGBC

(END) Dow Jones Newswires

November 15, 2021 02:00 ET (07:00 GMT)

1 Year Ergomed Chart

1 Year Ergomed Chart

1 Month Ergomed Chart

1 Month Ergomed Chart
ADVFN Advertorial
Your Recent History
LSE
ERGO
Ergomed
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220521 08:40:13